- Thinly traded nano cap Cerecor (CERC +16.7%) perks up on more than a 22x surge in volume, albeit on turnover of only 890K shares, as buyers spread the wealth stoked by Alkermes' (ALKS +33.5%) successful late-stage study of ALKS 5461 in major depressive disorder (MDD).
- Cerecor's lead product candidate is CERC-301, in Phase 2 development for the adjunctive treatment of MDD. Another mid-stage pipeline candidate for the same indication is CERC-501, a drug with a similar mechanism of action to ALKS 5461.